drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy)
drug_description
Autologous CD4/CD8-enriched T cells engineered with a CD19-directed chimeric antigen receptor (CAR) that recognizes CD19 and eliminates CD19+ B-lineage cells, inducing B-cell aplasia and aiming to reset humoral autoimmunity in refractory SLE.
nci_thesaurus_concept_id
C172103
nci_thesaurus_definition
A preparation of CD4+ and CD8+ autologous T-lymphocytes transduced with the lentiviral vector pLTG1563 expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD19 CAR-expressing CD4+/CD8+ T-cells MB-CART19.1 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous CD4+/CD8+ T cells engineered to express a CD19-directed chimeric antigen receptor that recognizes and eliminates CD19+ B-lineage cells, inducing B-cell aplasia, reducing autoantibody production, and aiming to reset humoral autoimmunity in refractory SLE.
drug_name
MB-CART19.1
nct_id_drug_ref
NCT06189157